Skip to main content

VivaVision Completes $46 Million Funding for Ophthalmology Therapies

VivaVision Biotech of Shanghai completed a $46 million Series D financing to develop novel drugs for chronic ocular or dermal inflammatory diseases. VivaVision is developing four molecules including its lead candidate, VVN001, a treatment for dry eye that is being tested in a Phase II study in the US . The company is also developing products for glaucoma. VivaVision was originally incubated by Vivo Biotech, a structure-based drug discovery CRO. The D round was led by Sequoia Capital China. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.